Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Overview

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development

Akshaya Bio Inc

Bavarian Nordic A/S

Boehringer Ingelheim GmbH

Etubics Corp

GeoVax Labs Inc

Merck KGaA

Minerva Biotechnologies Corp

NantKwest Inc

Peptron Inc

Transgene SA

Vaxil Bio Therapeutics Ltd

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles

BI-1361849 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CV-301 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ETBX-051 + ETBX-061 + ETBX-011 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Target MUC1 for Gastric Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GEOCM-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GI-6108 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GO-2032c - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ImMucin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesmulogene ancovacivec - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Breast Cancer and Pancreatic Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Peptides to Inhibit MUC1 for Metastatic Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tecemotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Brachyury Protein, KLK3 and MUC1 for Castration Resistant Prostate Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Mucin 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccines to Target MUC1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Product Development Milestones

Featured News & Press Releases

Mar 12, 2019: GeoVax selected as finalist for Vaccine Industry Excellence Awards

Nov 02, 2018: Bavarian Nordic announces initiation of clinical trial evaluating the combination therapy of CV301 and Durvalumab in metastatic colorectal and pancreatic cancers

Sep 20, 2018: Bavarian doses first patient in CV301 and atezolizumab Phase ll trial

Aug 10, 2018: HCRN study explores investigational vaccine therapy for metastatic colorectal cancer

Jul 11, 2018: Bavarian Nordic Announces Initiation of Phase 2 Trial Evaluating the Combination Therapy of CV301 and Nivolumab in Metastatic Colorectal Cancer

Jun 19, 2018: Exploring a New Treatment for Metastatic Colorectal Cancer

May 03, 2018: Israeli Cancer Research Firm Vaxil Granted 9th Patent for Immunotherapy Treatment

Mar 08, 2018: Bavarian Nordic Announces Phase 2 Trial Investigating Combination of Its Immunotherapy CV301 and Nivolumab in Microsatellite Stable Colorectal Cancer

Jan 16, 2018: First Patient Dosed in a Phase 2 Trial with Transgene TG4010 + Nivolumab + Chemotherapy for the First-Line Treatment of Lung Cancer (NSCLC)

Oct 30, 2017: Transgene to Present Additional Immunology Data from the TIME trial with TG4010 in patients with advanced lung cancer at SITC 2017

Oct 12, 2017: Peer Reviewed Scientific Publications Highlight TG4010's Ability to Induce Broad CD8+ Responses and its Synergistic Effects in Combination with Immune Checkpoint Inhibitors

Oct 09, 2017: GeoVax Chief Scientific Officer to Deliver Two Talks at World Vaccine Congress

Sep 11, 2017: Transgene Receives FDA IND Approval to Begin a Clinical Trial with TG4010 + Nivolumab + Chemotherapy in the First-Line Treatment of Lung Cancer

Aug 30, 2017: GeoVax Presents Preliminary Data for Cancer Vaccine

Jul 24, 2017: Cancer Immunotherapy Company Vaxil Appoints Dr. Terry Plasse as Chief Medical Officer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Mucin 1 - Pipeline Review, H1 2019'; Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 21 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes.

Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response.

The report 'Mucin 1 - Pipeline Review, H1 2019' outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, IND/CTA Filed and Preclinical stages are 7, 2, 1 and 7 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 2 and 1 molecules, respectively.

Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer, Prostate Cancer, Colon Cancer, Non-Small Cell Lung Cancer, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Lung Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Solid Tumor, Adenocarcinoma, Adenomas, Bladder Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Colorectal Cancer, Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Ovarian Cancer, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Transitional Cell Carcinoma (Urothelial Cell Carcinoma).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
- The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects
- The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope